In vivo studies in a mouse tumor model demonstrated that TfR targeting is a feasible strategy for nanoparticle-assisted co-delivery of anti-cancer drug and gene therapeutics for the treatment of lung cancer [135]. The gene discussed is TFRC; the disease is lung carcinoma.